Study Design
The study included 64 patients who underwent radical prostatectomy after
primary staging with mpMRI and 68Ga-PSMA PET/MRI,
between 2017 and 2019. Clinical (age, total prostate-specific antigen
[PSA], type of operation), radiological (length, volume, PI-RADS
score, maximum standardised uptake value [SUVmax] of
lesions, prostate volume), and pathological (biopsy and prostatectomy
International Society of Urological Pathology [ISUP] grade,
pathological tumour stage, pathological tumour and prostate volumes)
data were recorded. Prostate-specific antigen density (PSAD) was
calculated by dividing the total PSA by the prostate volume. Patients
who received neoadjuvant therapy, whose imaging tests were performed at
a different centre, or who had another known history of malignancy were
excluded from the study.